Advertisement

Topics

Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve

2018-02-25 20:52:13 | BioPortfolio

Published on BioPortfolio: 2018-02-25T20:52:13-0500

Clinical Trials [1614 Associated Clinical Trials listed on BioPortfolio]

Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could i...

Treatment of Refractory Angina Pectoris by Shock Wave Therapy

The purpose of this study is to determine that extracorporeal shock wave therapy (ESWT) is safe and effective for the treatment of refractory angina pectoris.

Extracorporeal Shockwave Myocardial Revascularization in Refractory Angina

This is a prospective cohort study to examine the efficacy of ESMR application in patients with refractory angina despite optimal medical therapy, not suitable for further PCI or CABG. Cha...

Cardiac Rehabilitation for the Treatment of Refractory Angina

The purpose of this study is to determine whether cardiac rehabilitation is a successful treatment for refractory angina, in relation to improvements in cardiovascular risk factors, physic...

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

The purpose of the study is to evaluate the safety and efficacy of catheter mediated endocardial adenovirus-mediated vascular endothelial growth factor-D (AdVEGF-D) regenerative gene trans...

PubMed Articles [12465 Associated PubMed Articles listed on BioPortfolio]

The Efficacy of Danshen Injection as Adjunctive Therapy in Treating Angina Pectoris: A Systematic Review and Meta-Analysis.

During the last 40 years, Danshen injection has been widely used as an adjunctive therapy for angina pectoris in China, but its efficacy is not yet well defined. The objective of this study was to ver...

Optimal Diagnostics and Therapy for Microvascular Angina Pectoris.

Patients with microvascular angina are characterized by angina pectoris with proof of myocardial ischemia in the absence of any relevant epicardial stenosis and without myocardial disease (type 1 coro...

Reducer, extracorporeal shockwave therapy or stem cells in refractory angina: a retrospective study.

The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives.

Despite available pharmacological and interventional therapies, refractory angina is a common and disabling clinical condition, and a major public health problem, which affects patients' quality-of-li...

Effect of Kuanxiong Aerosol () on Patients with Angina Pectoris: A Non-inferiority Multi-center Randomized Controlled Trial.

To evaluate the effect and safety of Kuanxiong Aerosol (, KA) on patients with angina pectoris.

Medical and Biotech [MESH] Definitions

An adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.

A selective adrenergic beta-1-blocking agent with no stimulatory action. It's binding to plasma albumin is weaker than alprenolol and it may be useful in angina pectoris, hypertension, or cardiac arrhythmias.

A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

ANGINA PECTORIS or angina-like chest pain with a normal coronary arteriogram and positive EXERCISE TEST. The cause of the syndrome is unknown. While its recognition is of clinical importance, its prognosis is excellent. (Braunwald, Heart Disease, 4th ed, p1346; Jablonski Dictionary of Syndromes & Eponymic Diseases, 2d ed). It is different from METABOLIC SYNDROME X, a syndrome characterized by INSULIN RESISTANCE and HYPERINSULINEMIA, that has increased risk for cardiovascular disease.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

More From BioPortfolio on "Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial